The Trump administration’s December 2025 executive order directed expedited review of marijuana’s placement under the Controlled Substances Act. In April 2026, the Department of Justice issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while leaving unlicensed and adult-use cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling to Schedule III opened June 29, concluded by mid-July, and featured closing briefs in August in which the agency argued marijuana no longer meets Schedule I criteria. An administrative law judge recommendation remains pending. Ongoing D.C. Circuit litigation challenging the April order saw a stay request denied in September, and House lawmakers have requested implementation details by September 30. These procedural steps and unresolved legal questions continue to shape trader assessments of further rescheduling timing.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$810,478 Vol.
30. Sep. 2026
30. September
<1%
31. Dezember
16%
$810,478 Vol.
30. September
$679 Vol.
<1%
31. Dezember
$200,228 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directed expedited review of marijuana’s placement under the Controlled Substances Act. In April 2026, the Department of Justice issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while leaving unlicensed and adult-use cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling to Schedule III opened June 29, concluded by mid-July, and featured closing briefs in August in which the agency argued marijuana no longer meets Schedule I criteria. An administrative law judge recommendation remains pending. Ongoing D.C. Circuit litigation challenging the April order saw a stay request denied in September, and House lawmakers have requested implementation details by September 30. These procedural steps and unresolved legal questions continue to shape trader assessments of further rescheduling timing.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Jul 31, 2026, 5:46 PM ET
Volumen
$810,478Enddatum
1. Jan. 2027Markt eröffnet
Jul 31, 2026, 5:46 PM ETAbwickler
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directed expedited review of marijuana’s placement under the Controlled Substances Act. In April 2026, the Department of Justice issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while leaving unlicensed and adult-use cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling to Schedule III opened June 29, concluded by mid-July, and featured closing briefs in August in which the agency argued marijuana no longer meets Schedule I criteria. An administrative law judge recommendation remains pending. Ongoing D.C. Circuit litigation challenging the April order saw a stay request denied in September, and House lawmakers have requested implementation details by September 30. These procedural steps and unresolved legal questions continue to shape trader assessments of further rescheduling timing.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$810,478Enddatum
1. Jan. 2027Markt eröffnet
Jul 31, 2026, 5:46 PM ETAbwickler
0x65070BE91...The Trump administration’s December 2025 executive order directed expedited review of marijuana’s placement under the Controlled Substances Act. In April 2026, the Department of Justice issued a final order moving FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while leaving unlicensed and adult-use cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling to Schedule III opened June 29, concluded by mid-July, and featured closing briefs in August in which the agency argued marijuana no longer meets Schedule I criteria. An administrative law judge recommendation remains pending. Ongoing D.C. Circuit litigation challenging the April order saw a stay request denied in September, and House lawmakers have requested implementation details by September 30. These procedural steps and unresolved legal questions continue to shape trader assessments of further rescheduling timing.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen